Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01283581 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections
A Phase 2 study, sponsored by Melinta Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 256
- Enrollment target
NCT01283581 is a Phase 2 study that has completed, run by Melinta Therapeutics. The registered enrollment target is 256 participants.
The verdict
NCT01283581, a Phase 2 study, has completed, sponsored by Melinta Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 256 participants
- Enrollment target
Study Summary
The purpose of this study is to compare clinical response to the measurement techniques of several objective measures of clinical efficacy for use in future ABSSSI (Acute Bacterial Skin and Skin Structure Infection) clinical trials
Interventions
- DRUG Vancomycin
- DRUG Linezolid
- DRUG Delafloxacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2011-01 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01283581
The ClinicalTrials.gov registry entry for NCT01283581 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Melinta Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vancomycin is the first listed.
NCT01283581 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01283581 about?
NCT01283581 is a clinical study titled "A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections". The purpose of this study is to compare clinical response to the measurement techniques of several objective measures of clinical efficacy for use in future ABSSSI (Acute Bacterial Skin and Skin Structure Infection) clinical trials
What is the current status of trial NCT01283581?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 256 participants. The study started on 2011-01. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01283581?
The interventions under investigation include: Vancomycin (DRUG), Linezolid (DRUG), Delafloxacin (DRUG).
Who is sponsoring clinical trial NCT01283581?
This trial is sponsored by Melinta Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.